Literature DB >> 35575798

DPYSL2 interacts with JAK1 to mediate breast cancer cell migration.

Areej Abu Rmaileh1, Balakrishnan Solaimuthu1, Anees Khatib1, Shirel Lavi1, Mayur Tanna1, Arata Hayashi1, Michal Ben Yosef1, Michal Lichtenstein1, Nir Pillar2, Yoav D Shaul1.   

Abstract

The intricate neuronal wiring during development requires cytoskeletal reorganization orchestrated by signaling cues. Because cytoskeletal remodeling is a hallmark of cell migration, we investigated whether metastatic cancer cells exploit axon guidance proteins to migrate. Indeed, in breast cancer patients, we found a significant correlation between mesenchymal markers and the expression of dihydropyrimidinase-like 2 (DPYSL2), a regulator of cytoskeletal dynamics in growing axons. Strikingly, DPYSL2 knockout in mesenchymal-like breast cancer cells profoundly inhibited cell migration, invasion, stemness features, tumor growth rate, and metastasis. Next, we decoded the molecular mechanism underlying this phenomenon and revealed an interaction between DPYSL2 and Janus kinase 1 (JAK1). This binding is crucial for activating signal transducer and activator of transcription 3 (STAT3) and the subsequent expression of vimentin, the promigratory intermediate filament. These findings identify DPYSL2 as a molecular link between oncogenic signaling pathways and cytoskeletal reorganization in migrating breast cancer cells.
© 2022 Abu Rmaileh et al.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35575798      PMCID: PMC9115587          DOI: 10.1083/jcb.202106078

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   8.077


  62 in total

1.  Characterization of the stemness potency of mammospheres isolated from the breast cancer cell lines.

Authors:  Saghar Yousefnia; Kamran Ghaedi; Farzad Seyed Forootan; Mohammad Hossein Nasr Esfahani
Journal:  Tumour Biol       Date:  2019-08

2.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Authors:  Balazs Györffy; Andras Lanczky; Aron C Eklund; Carsten Denkert; Jan Budczies; Qiyuan Li; Zoltan Szallasi
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

Review 3.  Structural Perspectives on Axon Guidance.

Authors:  Elena Seiradake; E Yvonne Jones; Rüdiger Klein
Journal:  Annu Rev Cell Dev Biol       Date:  2016-08-24       Impact factor: 13.827

4.  GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity.

Authors:  Takeshi Yoshimura; Yoji Kawano; Nariko Arimura; Saeko Kawabata; Akira Kikuchi; Kozo Kaibuchi
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 5.  The role of STAT3 in leading the crosstalk between human cancers and the immune system.

Authors:  Yu Wang; Yicheng Shen; Sinan Wang; Qiang Shen; Xuan Zhou
Journal:  Cancer Lett       Date:  2017-12-06       Impact factor: 8.679

6.  Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas.

Authors:  David Sarrió; Socorro María Rodríguez-Pinilla; Ana Dotor; Francisco Calero; David Hardisson; José Palacios
Journal:  Breast Cancer Res Treat       Date:  2006-03-15       Impact factor: 4.872

Review 7.  Neuropilin signalling in vessels, neurons and tumours.

Authors:  Claudio Raimondi; Christiana Ruhrberg
Journal:  Semin Cell Dev Biol       Date:  2013-01-11       Impact factor: 7.727

8.  SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis.

Authors:  Ruo-Chia Tseng; Shih-Hua Lee; Han-Shui Hsu; Ben-Han Chen; Wan-Ching Tsai; Ching Tzao; Yi-Ching Wang
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

9.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

10.  CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK.

Authors:  Binyan Lin; Yongxu Li; Tiepeng Wang; Yangmin Qiu; Zhenzhong Chen; Kai Zhao; Na Lu
Journal:  Oncogene       Date:  2020-08-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.